Organization
Nanchang People's Hospital
1 abstract
Abstract
A phase II trial of anlotinib and fulvestrant in patients with HR-positive and HER2-negative, secondary aromatase inhibitor–resistant, metastatic breast cancer.Org: The Third Hospital of Nanchang, Nanchang People's Hospital,